Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

• Disease Name: Severe Neonatal-Onset Encephalopathy With Microcephaly
• MONDO ID: (if available)
• Category: Genetic

Research Objectives

Please provide a comprehensive research report on Severe Neonatal-Onset Encephalopathy With Microcephaly covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

• What is the disease? Provide a concise overview.
• What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
• What are the common synonyms and alternative names?
• Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

• Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
• Risk Factors:

  Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

• Genetic risk factors (causal variants, susceptibility loci, modifier genes)
• Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
• Protective Factors:

  Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

• Genetic protective factors (protective variants, modifier alleles)
• Environmental protective factors (diet, lifestyle, exposures that reduce risk)
• Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

  Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

• Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

  Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

• Pathogenic Variants:
• Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
• Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
• Variant type/class (missense, frameshift, nonsense, splice-site, structural)
• Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
• Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
• Functional consequences (loss of function, gain of function, dominant negative)
• Modifier Genes: Genes that modify disease severity or expression
• Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

  Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

• Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

  Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

• Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

  Search first: CDC databases, WHO, PubMed, NHANES

• Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

  Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

• Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

  Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

• Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

  Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

• Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

  Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

• Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

  Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

• Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

  Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

• Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

  Search first: PubMed, Gene Ontology, Reactome

• Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

  Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

• Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Molecular Profiling (if available):
• Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
• Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
• Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
• Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
• Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
• Advanced Technologies (if applicable):
• Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
• Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
• Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
• Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

• Organ Level:
• Primary organs directly affected
• Secondary organ involvement (complications, secondary effects)
• Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

  Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

• Tissue and Cell Level:
• Specific tissue types affected (epithelial, connective, muscle, nervous)
• Specific cell populations targeted (with Cell Ontology terms)

  Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

• Subcellular Level:
• Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

  Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

• Localization:
• Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
• Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

• Onset:
• Typical age of onset (congenital, pediatric, adult, geriatric)
• Onset pattern (acute, subacute, chronic, insidious)

  Search first: OMIM, Orphanet, HPO, PubMed

• Progression:
• Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
• Progression rate (rapid, slow, variable)
• Disease course pattern (episodic, relapsing-remitting, progressive, stable)
• Disease duration (self-limited, chronic lifelong)

  Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

• Patterns:
• Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
• Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

• Epidemiology:
• Prevalence (cases per 100,000 at given time)
• Incidence (new cases per 100,000 per year)

  Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

• For Genetic Etiology:
• Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
• Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
• Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
• Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
• Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
• Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
• Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
• Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
• Population Demographics:
• Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
• Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
• Geographic distribution of specific variants
• Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
• Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

• Clinical Tests:
• Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
• Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
• Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
• Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
• Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
• Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
• Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
• Genetic Testing:

  Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

• Overview of recommended genetic testing approach
• Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
• Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
• Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
• Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
• Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
• Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
• FISH > Search first: ClinVar, cytogenetics databases, PubMed
• Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
• Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
• Omics-Based Diagnostics (if applicable):
• RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
• Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
• Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
• Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
• Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
• Clinical Criteria:
• Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
• Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
• Screening:
• Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

• Survival and Mortality:
• Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
• Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
• Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
• Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
• Morbidity and Function:
• Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
• Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
• Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
• Disease Course:
• Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
• Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
• Prediction:
• Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
• Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

• Pharmacotherapy:
• Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
• Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
• Advanced Therapeutics:
• Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
• Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
• RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
• Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
• Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
• Surgical and Interventional:
• Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
• Supportive and Rehabilitative:
• Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
• Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
• Experimental:
• Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
• Treatment Outcomes:
• Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
• Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
• Treatment Strategy:
• Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
• Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
• Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

13. Prevention

• Prevention Levels:
• Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
• Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
• Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
• Immunization: Vaccine strategies (if applicable)

  Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

• Screening and Early Detection:
• Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
• Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
• Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
• Behavioral Interventions: Lifestyle modifications to reduce risk

  Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

• Counseling: Genetic counseling (risk assessment, family planning guidance)

  Search first: NSGC resources, ACMG guidelines, GeneReviews

• Public Health:
• Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
• Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
• Prophylaxis: Preventive medications or procedures

  Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

• Taxonomy: Species affected (with NCBI Taxon identifiers)

  Search first: NCBI Taxonomy

• Breed: Specific breeds affected (with VBO identifiers if applicable)

  Search first: VBO (Vertebrate Breed Ontology)

• Gene: Orthologous genes in other species (with NCBI Gene IDs)

  Search first: NCBI Gene

• Natural Disease:
• Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
• Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
• Comparative Biology:
• Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
• Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
• Transmission (if applicable):
• Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
• Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

• Model Types:
• Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
• Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
• Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
• Genetic Models:
• Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
• Model Characteristics:
• Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
• Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
• Applications:
• Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
• Resources:
• Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

• Cite primary literature (PMID preferred) for all mechanistic and clinical claims
• Prioritize recent reviews and landmark papers
• Include direct quotes from abstracts where possible to support key statements
• Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (NCIT terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Severe Neonatal-Onset Encephalopathy With Microcephaly

Executive summary

Severe neonatal-onset encephalopathy with microcephaly is an ultra-rare, X-linked MECP2 loss-of-function (LoF) disorder, principally recognized in non-mosaic 46,XY infants. It represents the most severe end of the male MECP2-related spectrum: neurological impairment is evident from birth, often with hypotonia, respiratory failure or apnea, seizures, profound developmental impairment, acquired/progressive microcephaly, and death in infancy or early childhood. It must not be conflated with classic Rett syndrome, which usually affects heterozygous females after an initially normal developmental interval, or with MECP2 duplication syndrome, which results from increased rather than reduced MECP2 dosage. Open Targets identifies MECP2 as the sole associated target for this MONDO entity, supported by five evidence records (MONDO:0010397; ENSG00000169057). (OpenTargets Search: severe neonatal-onset encephalopathy with microcephaly-MECP2, pascualalonso2021mecp2relateddisordersin pages 2-4)

The evidence base is exceptionally small. Most disease-specific clinical evidence comes from individual patients, small series, and aggregated reviews of male MECP2 disorders; mechanistic, treatment, and model-organism evidence largely comes from Rett syndrome and Mecp2-null systems. Consequently, disease-specific prevalence, phenotype frequencies, survival curves, formal diagnostic criteria, validated biomarkers, and treatment-response statistics are unavailable.

Table: This table summarizes the best-supported knowledge-base fields for severe neonatal-onset encephalopathy with microcephaly (MONDO:0010397), emphasizing what is directly supported for this ultra-rare MECP2 loss-of-function disorder versus what is extrapolated from broader Rett syndrome and MECP2 biology literature.

1. Disease information

Definition and nomenclature

The preferred disease name is severe neonatal-onset encephalopathy with microcephaly. The principal identifier is MONDO:0010397. Literature labels include severe neonatal encephalopathy due to MECP2 mutation, male MECP2 encephalopathy, and, more broadly, male Rett encephalopathy. These labels are not perfectly interchangeable: “male Rett encephalopathy” has also been proposed for males who meet Rett clinical criteria, whereas the present entity is defined by impairment from birth and usually a much more rapidly lethal course. (OpenTargets Search: severe neonatal-onset encephalopathy with microcephaly-MECP2, pascualalonso2021mecp2relateddisordersin pages 4-5, pascualalonso2021mecp2relateddisordersin pages 2-4)

No disease-specific OMIM, Orphanet, MeSH, ICD-10, or ICD-11 code was verified in the retrieved evidence. Related but non-equivalent entries include Rett syndrome, OMIM 312750, and MECP2 duplication syndrome, OMIM 300260. A broad ICD code for neonatal encephalopathy or genetic neurodevelopmental disease may be used operationally, but it should not be represented as a disease-specific identifier. (pascualalonso2021mecp2relateddisordersin pages 5-7, dominguez2024epigeneticregulationand pages 2-4)

The foundational evidence is patient-derived, but modern resources aggregate those cases at disease level. A 2021 review reported 345 males with any MECP2 sequence variant in RettBASE, compared with 3,924 females; only an unspecified minority of those males had this severe neonatal phenotype. Thus, 345 is not a case count for MONDO:0010397. (pascualalonso2021mecp2relateddisordersin pages 2-4)

Critical nosological distinction

MECP2 is dosage-sensitive. Pathogenic sequence variants reducing MeCP2 function cause Rett/MECP2-LoF phenotypes, whereas duplication or triplication causes MECP2 duplication syndrome. Copy-number-gain statistics, infection susceptibility, and antisense strategies developed for duplication syndrome must therefore not be imported into this entity. (pascualalonso2021mecp2relateddisordersin pages 2-4, pascualalonso2021mecp2relateddisordersin pages 5-7, pascualalonso2021mecp2relateddisordersin pages 7-8)

2. Etiology and risk factors

The primary cause is a germline or mosaic pathogenic MECP2 variant that markedly reduces protein function in a hemizygous male. MECP2 lies at Xq28 and encodes methyl-CpG-binding protein 2. Reported classes across affected males include nonsense, frameshift, splice, missense, small insertion/deletion, and larger intragenic deletion variants. A representative severe allele is c.806delG, associated in the reviewed literature with severe neonatal encephalopathy and premature death. (pascualalonso2021mecp2relateddisordersin pages 2-4, gold2024rettsyndrome pages 2-3)

The major genetic modifiers are sex-chromosome complement and mosaicism. Non-mosaic 46,XY males carrying variants that cause Rett syndrome in females typically develop neonatal encephalopathy and die early. Males with somatic mosaicism or 47,XXY Klinefelter syndrome retain a population of cells expressing a normal allele and can instead manifest a more recognizable Rett phenotype. Variant position may also modify severity: one male cohort found higher clinical-severity scores for Rett-causing variants before codon 271 than for later variants. (pascualalonso2021mecp2relateddisordersin pages 4-5, pascualalonso2021mecp2relateddisordersin pages 2-4)

Variants may be de novo or inherited from a clinically normal or mildly affected heterozygous mother. Skewed X-chromosome inactivation can protect a carrier mother; therefore, maternal absence of obvious symptoms is not evidence against pathogenicity. Parental testing and careful evaluation for low-level mosaicism are essential. (bernardo2024xlinkedepilepsiesa pages 14-17, pascualalonso2021mecp2relateddisordersin pages 4-5)

No reproducible environmental, lifestyle, infectious, occupational, or dietary risk or protective factor is known. No validated protective MECP2 allele, modifier gene, founder mutation, or gene–environment interaction has been established for this specific phenotype. Environmental insults may worsen respiratory, nutritional, or seizure complications but are not known primary causes.

3. Phenotypes

The defining course is congenital or neonatal, severe, and generally progressive. The following HPO annotations are appropriate, although disease-specific percentages are unavailable:

• Neonatal encephalopathy — HP:0001298: impairment is present from birth rather than after the 6–18-month apparently normal interval typical of classic Rett syndrome.
• Microcephaly — HP:0000252, with progressive microcephaly — HP:0000253 or deceleration of head growth — HP:0000251 where longitudinal measurements support them. Exact neonatal-subgroup frequency is unknown.
• Hypotonia — HP:0001252: often severe and associated with poor motor acquisition, feeding difficulty, and respiratory compromise.
• Seizure — HP:0001250 and developmental and epileptic encephalopathy — HP:0200134: epilepsy can be early, severe, and medically refractory.
• Apnea — HP:0002104, respiratory insufficiency — HP:0002093, and abnormal breathing: respiratory arrest and ventilatory dependence are prominent in severe males.
• Global developmental delay — HP:0001263, profound intellectual disability — HP:0002187, absent speech — HP:0001344, and severe motor impairment.
• Additional plausible MECP2-spectrum annotations include feeding difficulty, dysphagia, growth failure, abnormal muscle tone, stereotypic movements, bruxism, sleep disturbance, diminished pain response, autonomic dysfunction, and scoliosis, but their frequencies in this exact neonatal entity have not been quantified. (bernardo2024xlinkedepilepsiesa pages 14-17, pascualalonso2021mecp2relateddisordersin pages 4-5, gold2024rettsyndrome pages 2-3, ballas2009non–cellautonomousinfluence pages 1-2)

A 2024 epilepsy review summarized the severe presentation as neonatal encephalopathy with respiratory arrest and seizures, with death generally within two years. This is a review-level synthesis rather than a prospective natural-history estimate. (bernardo2024xlinkedepilepsiesa pages 14-17)

Quality-of-life instruments such as EQ-5D, SF-36, or PROMIS have not been validated in this population. Functional burden is nevertheless extreme: affected infants may require continuous caregiving, ventilation, tube feeding, antiseizure therapy, and palliative support. Family and caregiver burden has not been quantified specifically.

4. Genetic and molecular information

Causal gene: MECP2; approved name methyl-CpG binding protein 2; Ensembl ENSG00000169057; cytoband Xq28. The gene has four exons and produces the MeCP2E1 and MeCP2E2 isoforms by alternative exon usage. MeCP2E1 disruption is sufficient to cause Rett-spectrum disease, whereas MeCP2E2 appears less essential for the classic phenotype. (OpenTargets Search: severe neonatal-onset encephalopathy with microcephaly-MECP2, vuu2023mecp2isan pages 4-5)

Pathogenic alleles are constitutional unless demonstrated to be post-zygotic mosaic; this is not a somatic-cancer disorder. Population frequencies should be checked variant by variant in gnomAD. Highly penetrant severe LoF variants are expected to be absent or exceptionally rare among unaffected hemizygous males, but no disease-wide carrier frequency was identified.

ACMG/AMP interpretation should integrate: predicted LoF mechanism; previous occurrence in females with Rett syndrome or males with neonatal encephalopathy; de novo status; segregation; maternal X-inactivation; phenotype specificity; population absence; and functional evidence. An inherited allele should not automatically be downgraded because the mother is asymptomatic. No validated modifier gene or disease-specific epigenetic signature is currently available. (pascualalonso2021mecp2relateddisordersin pages 4-5)

Large Xq28 duplications and triplications are a differential diagnosis, not a cause of this entity. Conversely, intragenic deletions disrupting MECP2 can be causal. Karyotype is relevant for detecting 47,XXY, while chromosomal microarray or dosage analysis distinguishes deletion from duplication.

5. Environmental information

No toxin, radiation exposure, pollution source, maternal behavior, diet, alcohol, tobacco exposure, or infectious agent has been shown to cause this Mendelian disorder. There is no zoonotic or transmissible component. Standard infection prevention, aspiration reduction, nutrition, and respiratory care may reduce secondary morbidity but do not alter the inherited cause.

6. Mechanism and pathophysiology

MeCP2 is an abundant postnatal nuclear protein, particularly in mature neurons. Its methyl-CpG-binding domain recognizes methylated DNA, while its repression region recruits chromatin regulators including NCoR/SMRT and HDAC3. It also interacts with SIN3A, CoREST, and a recently described TCF20–PHF14–HMG20A chromatin complex. Disease variants can disrupt DNA binding, protein stability, nuclear localization, or co-repressor recruitment. (gold2024rettsyndrome pages 2-3, dominguez2024epigeneticregulationand pages 2-4, vuu2023mecp2isan pages 4-5)

A useful causal chain is:

hemizygous MECP2 LoF → deficient reading of methylated DNA and abnormal chromatin/transcriptional regulation → dysregulated activity-dependent and maturation programs in neurons plus abnormal glial support → impaired dendritic arborization, spine/synaptic function and neural-network activity → severe developmental impairment, seizures, autonomic/respiratory instability, and reduced postnatal brain growth.

Neurons are the principal affected population, but pathology is not exclusively cell autonomous. In a landmark mouse/coculture study, MeCP2-null astrocytes and their conditioned medium failed to support normal dendritic morphology in wild-type or mutant hippocampal neurons. The abstract states: “mutant astrocytes from a RTT mouse model, and their conditioned medium, fail to support normal dendritic morphology.” This supports a soluble-factor-mediated astrocyte-to-neuron contribution. (Ballas et al., Nature Neuroscience, published March 2009; DOI: https://doi.org/10.1038/nn.2275; PMID 19234456.) (ballas2009non–cellautonomousinfluence pages 1-2)

Metabolic evidence suggests downstream mitochondrial, glucose, and cholesterol abnormalities. A 2024 analysis described multilevel MECP2-associated mitochondrial dysfunction, but its index male had a broader MECP2 phenotype rather than proven MONDO:0010397. Such findings should be annotated as secondary or spectrum-level evidence, not a diagnostic metabolic signature. (dominguez2024epigeneticregulationand pages 2-4, balicza2024multilevelevidenceof pages 1-2)

Suggested ontology annotations include GO:0006355 regulation of DNA-templated transcription, GO:0006325 chromatin organization, GO:0031175 neuron projection development, and GO:0048666 neuron development. Relevant cells are neuron CL:0000540, astrocyte CL:0000127, oligodendrocyte CL:0000128, and oligodendrocyte precursor cells. No disease-specific single-cell, spatial-transcriptomic, proteomic, metabolomic, lipidomic, or CRISPR-screen dataset was identified.

7. Anatomical structures affected

The primary organ is the brain and the primary system is the central nervous system: UBERON:0000955 brain and UBERON:0001017 central nervous system. Relevant neural tissues include cerebral cortex and hippocampal circuitry, although no single region explains the multisystem phenotype. Secondary involvement includes respiratory musculature and brainstem autonomic networks, gastrointestinal/feeding systems, musculoskeletal tissues, and growth regulation. (gold2024rettsyndrome pages 2-3, ballas2009non–cellautonomousinfluence pages 1-2)

At subcellular level, the principal compartment is the nucleus, including chromatin and transcriptional co-repressor complexes. Downstream abnormalities involve dendrites, dendritic spines, synapses, and potentially mitochondria. Disease lateralization is not expected; abnormalities are bilateral/systemic.

8. Temporal development

Onset is congenital or neonatal and may be acute in presentation—hypotonia, apnea, feeding failure, or seizures—but reflects an ongoing developmental disorder. Unlike classic Rett syndrome, there is generally no clearly normal early developmental phase. The course is chronic, rapidly progressive, and often fatal in infancy or early childhood. No validated stages, remission pattern, or disease-specific critical intervention window has been defined. (bernardo2024xlinkedepilepsiesa pages 14-17, pascualalonso2021mecp2relateddisordersin pages 2-4)

The neonatal and early postnatal period is biologically important because MeCP2 abundance increases with neuronal maturation. Preclinical rescue studies imply that established dysfunction is not wholly irreversible, but safe human dosage control is crucial because both deficiency and excess are pathogenic. (ballas2009non–cellautonomousinfluence pages 1-2, percy2024rettsyndromethe pages 13-15, jagadeeswaran2025preclinicalmilestonesin pages 2-3)

9. Inheritance and population

Inheritance is X-linked. Severe expression is expected in hemizygous males, while heterozygous females show variable expression because of X-inactivation. A carrier mother has a 50% probability of transmitting the allele in each pregnancy; transmitted pathogenic variants generally place sons at high risk of severe disease and daughters at risk of a Rett-spectrum phenotype, although actual expression depends on the allele and X-inactivation. De novo cases carry a low but non-zero recurrence risk because parental germline mosaicism may occur.

Penetrance is high for established severe LoF alleles in non-mosaic hemizygous males, but expressivity across all MECP2 variants is broad. Anticipation is not recognized. No founder effect, ethnic enrichment, geographic clustering, carrier-frequency estimate, consanguinity association, or reliable sex ratio for this exact entity is available. Its apparent male predominance is mechanistic and ascertainment-related, not an epidemiological male:female ratio from a registry.

No incidence or prevalence per 100,000 has been established. The approximately 1-in-10,000 figure cited for Rett syndrome must not be applied to this neonatal male condition. (dominguez2024epigeneticregulationand pages 2-4)

10. Diagnostics

Diagnosis requires recognition of a severe neonatal neurologic phenotype followed by molecular confirmation. Recommended evaluation includes:

1. Rapid trio genome or exome sequencing, or a comprehensive neonatal/developmental-epileptic encephalopathy panel that includes MECP2.
2. High-depth review for post-zygotic mosaicism; Sanger sequencing alone may miss low-level mosaicism.
3. Copy-number analysis to detect intragenic deletion and exclude MECP2 duplication/triplication.
4. Parental testing, maternal clinical assessment, and consideration of maternal X-inactivation studies.
5. Karyotype when 47,XXY is plausible.
6. Brain MRI, serial head circumference, EEG/video-EEG, swallow and nutrition assessment, cardiorespiratory monitoring, and testing for alternative metabolic/infectious causes according to presentation. (pascualalonso2021mecp2relateddisordersin pages 4-5, pascualalonso2021mecp2relateddisordersin pages 2-4)

WGS is particularly useful when panel/WES findings are negative because it can identify coding, splice, structural, and mosaic variants in one analysis. RNA sequencing may clarify suspected splice variants, but no validated disease-specific transcriptomic assay exists. CMA, FISH, and MLPA are adjuncts for dosage/cytogenetic questions; mitochondrial DNA and repeat-expansion testing are not routine unless the phenotype suggests a separate diagnosis.

Differential diagnoses include hypoxic–ischemic encephalopathy; congenital infection; metabolic/mitochondrial encephalopathy; other neonatal developmental and epileptic encephalopathies; CDKL5, FOXG1, SCN2A, KCNQ2, STXBP1, and PCDH19-related disorders; classic/atypical Rett syndrome; and MECP2 duplication syndrome. There are no universally accepted clinical criteria specific to MONDO:0010397 and no population newborn screen. Molecular cascade testing is appropriate after a familial variant is identified.

11. Outcome and prognosis

The historical prognosis for a non-mosaic 46,XY infant with a severe Rett-causing MECP2 allele is poor. Respiratory arrest, refractory epilepsy, aspiration/feeding complications, and global neurologic deterioration contribute to early mortality; reviews commonly describe death in the first year or by two years. Exact median survival and 5- or 10-year survival are unavailable. Mosaic and 47,XXY males, and males with hypomorphic variants, can survive much longer and should not be pooled with this entity. (pascualalonso2021mecp2relateddisordersin pages 2-4, bernardo2024xlinkedepilepsiesa pages 14-17)

Long-term recovery without molecular therapy is not expected. Disability is profound. No validated prognostic biomarker exists beyond genotype/function, mosaic fraction, sex-chromosome complement, respiratory dependence, and overall neurologic severity. The 2024 Rett primer cautions that life-expectancy estimates for boys with MECP2 variants remain unavailable because the phenotype is still being delineated. (gold2024rettsyndrome pages 2-3)

12. Treatment and current applications

There is no approved disease-modifying treatment specifically for this disorder. Management is individualized and multidisciplinary:

• respiratory monitoring, airway clearance, oxygen or ventilation, and aspiration prevention;
• standard genotype-agnostic antiseizure treatment, with epilepsy-specialist management for drug resistance;
• swallow evaluation, caloric support, reflux/constipation treatment, and nasogastric or gastrostomy feeding when appropriate;
• physical, occupational, communication, and positioning therapy;
• surveillance for scoliosis, contractures, sleep disturbance, dysautonomia, and bone disease;
• early palliative-care involvement and family psychosocial support.

Suggested NCIT intervention concepts are Supportive Care, Anticonvulsant Therapy, Mechanical Ventilation, Gastrostomy, Physical Therapy, Occupational Therapy, and Genetic Counseling.

Trofinetide, a synthetic IGF1-related tripeptide analogue, became the first FDA-approved Rett-specific drug in March 2023. However, its pivotal evidence concerns Rett syndrome—not neonatal male MECP2 encephalopathy—and improvement was incremental rather than curative. There is no evidence supporting routine extrapolation to critically ill neonates. (Percy et al., published September 2024; DOI: https://doi.org/10.1007/s40263-024-01106-y.) (percy2024rettsyndromethe pages 13-15, gold2024rettsyndrome pages 14-14)

MECP2 gene replacement is mechanistically attractive but dosage must be tightly controlled. RTT-focused trials include NGN-401 (NCT05898620) and TSHA-102/REVEAL (NCT06152237). Retrieved trial records also included an AAV-MECP2 study NCT06856759 (early phase 1, active but not recruiting, target n=8) and an observational gene-editing study NCT05740761 (recruiting, n=40). These programs generally enroll older children and do not establish safety or efficacy in neonatal males. Neonatal administration in rodents corresponds developmentally to preterm human infancy, a stage not covered by current trials. (percy2024rettsyndromethe pages 13-15, jagadeeswaran2025preclinicalmilestonesin pages 2-3)

Relevant observational resources include the completed Rett natural-history study NCT02738281 (n=1,044), completed biobank NCT02705677 (n=752), recruiting Rett registry NCT05432349 (planned n=3,000), and male MECP2 dysautonomia study NCT04502199 (planned n=20; status unknown). None is a disease-specific interventional trial for MONDO:0010397.

13. Prevention

There is no vaccine, lifestyle intervention, environmental avoidance strategy, or prophylactic medication that prevents a de novo MECP2 variant. Primary prevention is reproductive: genetic counseling, maternal and family testing, prenatal diagnosis, and—where legally and ethically available—preimplantation genetic testing for a known familial variant. Secondary prevention consists of rapid molecular diagnosis and anticipatory respiratory, seizure, and feeding management. Tertiary prevention targets aspiration, infection, malnutrition, contracture, and caregiver burden. (pascualalonso2021mecp2relateddisordersin pages 4-5)

14. Other species and natural disease

No naturally occurring veterinary counterpart, affected breed, or zoonotic transmission was identified. MECP2 orthologues are evolutionarily conserved across vertebrates, but published animal disease is predominantly engineered rather than naturally occurring. Comparative pathology supports conservation of neuronal maturation, synaptic, respiratory, and motor consequences of MeCP2 deficiency.

15. Model organisms

The principal model is the hemizygous Mecp2-null male mouse (Mecp2−/y), which develops an early severe neurological phenotype and mortality and therefore models the human male LoF state more directly than heterozygous female mice. Conditional deletion in neural progenitors approximates the global-null phenotype; deletion in post-mitotic neurons produces a similar but milder syndrome, demonstrating a major requirement in mature neurons. Genetic reactivation of normal Mecp2 can substantially rescue established abnormalities, establishing biological reversibility. (pascualalonso2021mecp2relateddisordersin pages 8-10, ballas2009non–cellautonomousinfluence pages 1-2, jagadeeswaran2025preclinicalmilestonesin pages 2-3)

Human systems include patient fibroblast-derived iPSCs, differentiated neurons, astrocyte–neuron cocultures, and region-specific brain organoids. Reported experimental rescue strategies include increasing KCC2, IGF1-related treatment, and LIN28 suppression; these remain preclinical and were developed primarily in Rett models. Organoid phenotypes vary by mutation and genetic background, which is useful for studying allelic heterogeneity but limits direct quantitative translation. (pascualalonso2021mecp2relateddisordersin pages 8-10)

Evidence-quality conclusion

The disease–gene relationship is strong, but disease-specific natural-history and therapeutic evidence is weak because the entity is defined from very few severe male cases. The most defensible knowledge-base representation is therefore: high confidence in MECP2 causality, X-linked inheritance, neonatal onset, severe neurologic/respiratory phenotype, microcephaly, and poor prognosis; moderate confidence in detailed phenotype expansion; and explicitly extrapolated evidence for molecular pathways, supportive management, biomarkers, and emerging Rett-directed therapies. Recent 2023–2024 work has materially advanced MECP2 chromatin biology, mitochondrial hypotheses, Rett gene therapy, and therapeutic development, but it has not yet produced a validated intervention for severe neonatal-onset encephalopathy with microcephaly. (dominguez2024epigeneticregulationand pages 2-4, percy2024rettsyndromethe pages 13-15, jagadeeswaran2025preclinicalmilestonesin pages 2-3, balicza2024multilevelevidenceof pages 1-2)

References

1. (OpenTargets Search: severe neonatal-onset encephalopathy with microcephaly-MECP2): Open Targets Query (severe neonatal-onset encephalopathy with microcephaly-MECP2, 1 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

2. (pascualalonso2021mecp2relateddisordersin pages 2-4): Ainhoa Pascual-Alonso, Antonio F. Martínez-Monseny, Clara Xiol, and Judith Armstrong. Mecp2-related disorders in males. International Journal of Molecular Sciences, 22:9610, Sep 2021. URL: https://doi.org/10.3390/ijms22179610, doi:10.3390/ijms22179610. This article has 57 citations.

3. (bernardo2024xlinkedepilepsiesa pages 14-17): Pia Bernardo, Claudia Cuccurullo, Marica Rubino, Gabriella De Vita, Gaetano Terrone, Leonilda Bilo, and Antonietta Coppola. X-linked epilepsies: a narrative review. International Journal of Molecular Sciences, 25:4110, Apr 2024. URL: https://doi.org/10.3390/ijms25074110, doi:10.3390/ijms25074110. This article has 14 citations.

4. (gold2024rettsyndrome pages 2-3): Wendy A. Gold, Alan K. Percy, Jeffrey L. Neul, Stuart R. Cobb, Lucas Pozzo-Miller, Jasmeen K. Issar, Bruria Ben-Zeev, Aglaia Vignoli, and Walter E. Kaufmann. Rett syndrome. Nov 2024. URL: https://doi.org/10.1038/s41572-024-00568-0, doi:10.1038/s41572-024-00568-0. This article has 82 citations.

5. (dominguez2024epigeneticregulationand pages 2-4): Gaea Dominguez, Yongji Wu, and Jian Zhou. Epigenetic regulation and neurodevelopmental disorders: from mecp2 to the tcf20/phf14 complex. Genes, 15:1653, Dec 2024. URL: https://doi.org/10.3390/genes15121653, doi:10.3390/genes15121653. This article has 7 citations.

6. (percy2024rettsyndromethe pages 1-2): Alan K. Percy, Amitha Ananth, and Jeffrey L. Neul. Rett syndrome: the emerging landscape of treatment strategies. CNS Drugs, 38:851-867, Sep 2024. URL: https://doi.org/10.1007/s40263-024-01106-y, doi:10.1007/s40263-024-01106-y. This article has 41 citations and is from a peer-reviewed journal.

7. (pascualalonso2021mecp2relateddisordersin pages 5-7): Ainhoa Pascual-Alonso, Antonio F. Martínez-Monseny, Clara Xiol, and Judith Armstrong. Mecp2-related disorders in males. International Journal of Molecular Sciences, 22:9610, Sep 2021. URL: https://doi.org/10.3390/ijms22179610, doi:10.3390/ijms22179610. This article has 57 citations.

8. (pascualalonso2021mecp2relateddisordersin pages 7-8): Ainhoa Pascual-Alonso, Antonio F. Martínez-Monseny, Clara Xiol, and Judith Armstrong. Mecp2-related disorders in males. International Journal of Molecular Sciences, 22:9610, Sep 2021. URL: https://doi.org/10.3390/ijms22179610, doi:10.3390/ijms22179610. This article has 57 citations.

9. (vuu2023mecp2isan pages 4-5): Yen My Vuu, Chris-Tiann Roberts, and Mojgan Rastegar. Mecp2 is an epigenetic factor that links dna methylation with brain metabolism. International Journal of Molecular Sciences, 24:4218, Feb 2023. URL: https://doi.org/10.3390/ijms24044218, doi:10.3390/ijms24044218. This article has 60 citations.

10. (ballas2009non–cellautonomousinfluence pages 1-2): Nurit Ballas, Daniel T Lioy, Christopher Grunseich, and Gail Mandel. Non–cell autonomous influence of mecp2-deficient glia on neuronal dendritic morphology. Nature Neuroscience, 12:311-317, Mar 2009. URL: https://doi.org/10.1038/nn.2275, doi:10.1038/nn.2275. This article has 574 citations and is from a highest quality peer-reviewed journal.

11. (pascualalonso2021mecp2relateddisordersin pages 4-5): Ainhoa Pascual-Alonso, Antonio F. Martínez-Monseny, Clara Xiol, and Judith Armstrong. Mecp2-related disorders in males. International Journal of Molecular Sciences, 22:9610, Sep 2021. URL: https://doi.org/10.3390/ijms22179610, doi:10.3390/ijms22179610. This article has 57 citations.

12. (balicza2024multilevelevidenceof pages 1-2): Peter Balicza, Andras Gezsi, Mariann Fedor, Judit C. Sagi, Aniko Gal, Noemi Agnes Varga, and Maria Judit Molnar. Multilevel evidence of mecp2-associated mitochondrial dysfunction and its therapeutic implications. Frontiers in Psychiatry, Jan 2024. URL: https://doi.org/10.3389/fpsyt.2023.1301272, doi:10.3389/fpsyt.2023.1301272. This article has 3 citations.

13. (percy2024rettsyndromethe pages 13-15): Alan K. Percy, Amitha Ananth, and Jeffrey L. Neul. Rett syndrome: the emerging landscape of treatment strategies. CNS Drugs, 38:851-867, Sep 2024. URL: https://doi.org/10.1007/s40263-024-01106-y, doi:10.1007/s40263-024-01106-y. This article has 41 citations and is from a peer-reviewed journal.

14. (gold2024rettsyndrome pages 14-14): Wendy A. Gold, Alan K. Percy, Jeffrey L. Neul, Stuart R. Cobb, Lucas Pozzo-Miller, Jasmeen K. Issar, Bruria Ben-Zeev, Aglaia Vignoli, and Walter E. Kaufmann. Rett syndrome. Nov 2024. URL: https://doi.org/10.1038/s41572-024-00568-0, doi:10.1038/s41572-024-00568-0. This article has 82 citations.

15. (jagadeeswaran2025preclinicalmilestonesin pages 2-3): Indumathy Jagadeeswaran, Jiyoung Oh, and Sarah E. Sinnett. Preclinical milestones in mecp2 gene transfer for treating rett syndrome. Developmental Neuroscience, 47:147-156, May 2024. URL: https://doi.org/10.1159/000539267, doi:10.1159/000539267. This article has 5 citations and is from a peer-reviewed journal.

16. (pascualalonso2021mecp2relateddisordersin pages 8-10): Ainhoa Pascual-Alonso, Antonio F. Martínez-Monseny, Clara Xiol, and Judith Armstrong. Mecp2-related disorders in males. International Journal of Molecular Sciences, 22:9610, Sep 2021. URL: https://doi.org/10.3390/ijms22179610, doi:10.3390/ijms22179610. This article has 57 citations.

Artifacts

• Edison artifact artifact-00